CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, confirmed that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.
- The company rejects current rumors of an acquisition
TÜBINGEN, Germany and BOSTON, March 15, 2020 (GLOBE NEWSWIRE) -- CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, confirmed today that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.
As a consequence, the company is in contact with especially CEPI and many other organizations and authorities worldwide, however, abstains from commenting on speculations and rejects allegations about offers for acquisition of the company or its technology.
Based on its inherent mode of action, CureVac sees mRNA as one of the most potent molecules to provide fast and efficient solutions in outbreak scenarios, such like the Coronavirus. With in-house expertise of over two decades and the company’s deep scientific understanding, CureVac is leveraging its potent vaccine platform to focus on developing a potent, efficacious, safe and fast to produce vaccine against Covid-19.
CureVac recently announced successful vaccination results in its Rabies program, fully protecting humans with two doses of only 1 microgram (1 millionth of a gram). These results are encouraging when thinking of supplying populations and people worldwide in a pandemic scenario.
The company also has long and strong manufacturing expertise for mRNA-based vaccines and therapeutics since 2006. At this time, CureVac is working on expanding its manufacturing capacities to be able to provide up to billions of doses for outbreak situations like Covid-19.
Mariola Fotin-Mleczek, Chief Technology Officer of CureVac, commented: “Nature has invented mechanisms to activate our immune system against infectious diseases. With our unique messanger RNA technology, we mimic nature and give our body the information how to fight against the virus. The combination of mRNA science, disease understanding, formulation and production expertise make CureVac a unique player to fight against any infectious disease, no matter whether they are seasonal or pandemic.”
About CureVac AG
CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac has received significant investments, amongst others from dievini Hopp BioTech holding and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including CEPI, Boehringer Ingelheim, Eli Lilly & Co, Genmab, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.
CureVac Media Contact
Thorsten Schüller, Head of Corporate Communications
Tel: +49 (0)7071 9883-1577
Email: thorsten.schueller@curevac.com
